BIO 2021 Notebook: A Breakthrough Year For Emerging Companies?

 
• By Scrip Team and Pink Sheet Team

News and views from day two of the BIO Digital annual meeting include the increasing number of small companies driving US product approvals, the US FDA's Patrizia Cavazzoni on science vs. emotion at advisory committees and Merck & Co.'s Julie Gerberding on the need for continued HIV/AIDS research.

BIO 2021 Notebook - Day 2
BIO included updates on the Reagan-Udall RWE accelerator project and the need to put digital product data into context for stakeholders.

More from Drug Pricing

More from Scrip